Phosphorylation and compactness of neurofilaments in multiple sclerosis: Indicators of axonal pathology

Experimental Neurology

Volumn 213, Issue 2, 2008, Pages 326-335

  Petzold, Axel ^a   Gveric, Djordje ^a   Groves, Mike ^a   Schmierer, Klaus ^a   Grant, Donna ^a   Chapman, Miles ^a   Keir, Geoffrey ^a   Cuzner, Louise ^a   Thompson, Edward J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Axonal injury; Multiple sclerosis; Neurofilament phosphoforms

Indexed keywords

CYTOSKELETON PROTEIN;

ADULT; AGED; ARTICLE; BRAIN; CONTROLLED STUDY; CYTOARCHITECTURE; DEPHOSPHORYLATION; DISEASE DURATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NERVE FIBER TRANSPORT; NEUROFILAMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SPINAL CORD;

ADULT; AGED; AGED, 80 AND OVER; AXONS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; PHOSPHORYLATION; PROTEIN ISOFORMS;

EID: 51349115914     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.06.008     Document Type: Article

References (43)

1. Ackerley S., Grierson A.J., et al. Glutamate slows axonal transport of neurofilaments in transfected neurons. J. Cell. Biol. 150 (2000) 165-176
2. Akassoglou K., Yu W.M., Akpinar P., and Strickland S. Fibrin inhibits peripheral nerve remyelination by regulating Schwann cell differentiation. Neuron 33 (2002) 861-875
3. Bitsch A., Schuchard J., Bunkowski S., et al. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 123 (2000) 1174-1183
4. Bjartmar C., and Trapp B.D. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 14 (2001) 271-278
5. Brownlees J., Yates A., Bajaj N.P., et al. Phosphorylation of neurofilament heavy chain side-arms by stress activated protein kinase-1b/Jun N-terminal kinase-3. J. Cell. Sci. 113 (2000) 401-407 (February)
6. Ciccarelli O., Werring D.J., Barker G.J., et al. A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging-evidence of Wallerian degeneration. J. Neurol. 250 (2003) 287-292
7. Coleman M.P., and Perry V.H. Axon pathology in neurological disease: a neglected therapeutic target. Trends. Neurosci. 25 (2002) 532-537
8. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., Gudz T., Macklin W.B., Lewis D.A., Fox R.J., Rudick R., Mirnics K., and Trapp B.D. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 59 (2006) 478-489
9. Esiri M.M. The interplay between inflammation and neurodegeneration in CNS disease. J. Neuroimmunol. 184 (2007) 4-16
10. Ferguson B., Matyszak M.K., Esiri M.M., and Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 120 (1997) 393-399
11. Geurts J.J., Wolswijk G., Bo L., et al. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 126 (2003) 1755-1766
12. Gilgun-Sherki Y., Panet H., Melamed E., and Offen D. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res. 989 (2003) 196-204
13. Goldstein M.E., Sternberger N.H., and Sternberger L.A. Phosphorylation protects neurofilaments against proteolysis. J. Neuroimmunol. 14 (1987) 149-160
14. Grant P., and Pant H.C. Neurofilament protein synthesis and phosphorylation. J. Neurocytol. 29 (2000) 843-872 (Nov-Dec)
15. Gveric D., Cuzner M.L., and Newcombe J. Insulin-like growth factors and binding proteins in multiple sclerosis plaques. Neuropathol. Appl. Neurobiol. 25 (1999) 215-225
16. Gveric D., Hanemaaijert R., Newcombe J., van Lent N.A., Stier C.F.M., and Cuzner M.J. Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain 124 (2001) 1978-1988
17. Gveric D., Herrera B., Petzold A., et al. Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 126 (2003) 1590-1598
18. Jurewicz A., Matysiak M., Raine C.S., and Selmaj K. Soluble NogoA, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. Neurology 68 (2007) 283-287
19. Karnezis T., Mandemakers W., McQualter J.L., et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat. Neurosci. 7 (2004) 736-744
20. Lassmann H., Bruck W., and Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 17 (2007) 210-218
21. Lee M.K., and Cleveland D.W. Neuronal intermediate filaments. Ann. Rev. Neurosci. 19 (1996) 187-217
22. Losseff N.A., Webb S.L., O'Riordan J.I., et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119 (1996) 701-708
23. Lovas G., Szilagyi N., Majtenyi K., Palkovits M., and Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 123 (2000) 308-317
24. Moss D.W., and Henderson A.R. Tietz Textbook of Clinical Chemistry, chapter Enzymes. 2nd (1994), WB Saunders Company, Philadelphia, Pensylvania 19106 735-896
25. Newcombe J. Distribution of glial fibrillary acidic protein in gliosed human white matter. J. Neurochem. 47 (1986) 1713-1719
26. Newcombe J., and Cuzner M.L. Microglia-derived macrophages in early multiple sclerosis plaques. Neuropathol. Appl. Neurobiol. 22 (1996) 207-215
27. Newcombe J., Naik N., and Cuzner M.L. Monoclonal antibody 14E recognizes an antigen common to human oligodendrocytes, Schwann cells, Bergmann glia, and a subpopulation of reactive glia. Neurochem. Res. 17 (1992) 933-938
28. Pant H.C. Dephosphorylation of neurofilament proteins enhances their susceptibility to degradation by calpain. Biochem. J. 256 (1988) 665-668
29. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci. 233 (2005) 183-198
30. Petzold A., Eikelenboom M.J., Gveric D., Keir G., Chapman M., Lazeron R.H., et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 125 (2002) 1462-1473
31. Petzold A., Keir G., Green A.J.E., et al. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J. Immunol. Methods. 278 (2003) 179-190
32. Petzold A., Baker D., Pryce G., et al. Quantification of neurodegeneration by measurement of brain-specific proteins. J. Neuroimmunol. 138 (2003) 45-48
33. Petzold A., Eikelenboom M.J., Keir G., et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: a 3-year follow-up study. J. Neurol. Neurosurg. Psychiatry 76 (2005) 206-211
34. Pitt D., Werner P., and Raine C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6 (2000) 67-70
35. Schwab M.E. Nogo and axon regeneration. Curr. Opin. Neurobiol. 14 (2004) 118-124
36. Schwarzschild M.A., Cole R.L., Meyers M.A., and Hyman S.E. Contrasting calcium dependencies of SAPK and ERK activations by glutamate in cultured striatal neurons. J. Neurochem. 72 (1999) 2248-2255
37. Shaw G., Yang C., Ellis R., Anderson K., et al. Hyperphosphorylated neurofilament NF-H is a serum biomarker for axonal injury. Biochem. Biophys. Res. Comm. 336 (2005) 1268-1277
38. Sternberger L.A., and Sternberger N.H. Monoclonal antibodies distinguish phosphorylated and non-phosphorylated forms of neurofilaments in situ. Proc. Natl. Acad. Sci. U.S.A. 82 (1983) 6126-6130
39. Trapp B.D., Peterson J.P., et al. Axonal transection in the lesions of multiple sclerosis. N. Eng. J. Med. 338 (1998) 278-285
40. Watson D.F., Griffin J.W., Fittro K.P., and Hoffman P.N. Phosphorylation- dependent immunoreactivity of neurofilaments increases during axonal maturation and beta,beta-iminodipropionitrile intoxication. J. Neurochem. 53 (1989) 1818-1829
41. Werner P., Pitt D., and Raine C.S. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann. Neurol. 50 (2001) 169-180
42. Xia Z., Dudek H., Miranti C.K., and Greenberg M.E. Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. J. Neurosci. 16 (1996) 5425-5436
43. Vargas M.E., and Barres B.A. Why is Wallerian degeneration in the CNS so slow?. Annu. Rev. Neurosci. 30 (2007) 153-179